Spatial analysis of recurrent glioblastoma reveals perivascular niche organization
2024 · JCI Insight · 17 citations
https://doi.org/10.1172/jci.insight.179853
R
Rachael A. Vaubel
Mayo Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
172
Papers
2.0K
Citations
18
h-index
23
i10-index
Rachael A. Vaubel is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Glioma Diagnosis and Treatment & Radiopharmaceutical Chemistry and Applications & Cancer Research and Treatments. The author has an h-index of 18, co-authored 147 publications.
ORCID: 0000-0001-8842-5975Papers by this author
worksModeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628
2024 · Molecular Cancer Therapeutics · 3 citations
https://doi.org/10.1158/1535-7163.mct-24-0664
Figure S8 from Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <i>In Vivo</i> Efficacy in Glioblastoma
2024 · 0 citations
https://doi.org/10.1158/1535-7163.24935413
Figure S5 from Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <i>In Vivo</i> Efficacy in Glioblastoma
2024 · 0 citations
https://doi.org/10.1158/1535-7163.24935422.v1
Figure S8 from Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <i>In Vivo</i> Efficacy in Glioblastoma
2024 · 0 citations
https://doi.org/10.1158/1535-7163.24935413.v1
Figure S1 from Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <i>In Vivo</i> Efficacy in Glioblastoma
2024 · 0 citations
https://doi.org/10.1158/1535-7163.24935434
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat